Company Profile
Aptevo Therapeutics Stock Price, News & Analysis
Company overview
Business overview
Aptevo Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Aptevo Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Aptevo Therapeutics follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Aptevo Therapeutics sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Why the stock is moving
APVO is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Aptevo's mipletamig data gave the company a clearer story in frontline AML. The 86 percent clinical benefit rate and the absence of cytokine release syndrome are the details that matter, especially now that the company is also widening its CD3 pipeline and adding trispecific candidates.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update
Source: Aptevo Therapeutics
- 02
- 03
- 04
Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split
Source: Aptevo Therapeutics
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.